Answer:
In the scenario you described, if a patient is given medication to slow down the production of hemoglobin and subsequently experiences severe adverse effects leading to their death, the lawsuit might not typically name a specific organelle. Instead, the lawsuit would likely focus on the drug company, alleging that the medication had harmful or fatal side effects.
The specific organelle responsible for hemoglobin production in red blood cells is the **ribosome.** However, it is unusual to name an organelle in a lawsuit; legal action would typically involve the drug company's product, its safety, and its impact on the patient's health. The lawsuit might investigate whether the medication had unintended consequences on the patient's red blood cell production, potentially implicating the drug's formulation or manufacturing.